$725 Million is the total value of SPHERA FUNDS MANAGEMENT LTD.'s 110 reported holdings in Q2 2018. The portfolio turnover from Q1 2018 to Q2 2018 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| LPSN | Exit | LIVEPERSON INC | $0 | – | -136 | -100.0% | 0.00% | – |
| ATHX | Exit | ATHERSYS INC | $0 | – | -773 | -100.0% | 0.00% | – |
| VSTO | Exit | VISTA OUTDOOR INC | $0 | – | -6,000 | -100.0% | -0.02% | – |
| XRAY | Exit | DENTSPLY SIRONA INC | $0 | – | -2,500 | -100.0% | -0.02% | – |
| GLIBA | Exit | GCI LIBERTY INC | $0 | – | -3,000 | -100.0% | -0.02% | – |
| SEE | Exit | SEALED AIR CORP NEW | $0 | – | -4,500 | -100.0% | -0.03% | – |
| CMCSA | Exit | COMCAST CORP NEWcl a | $0 | – | -10,000 | -100.0% | -0.05% | – |
| WSO | Exit | WATSCO INC | $0 | – | -2,100 | -100.0% | -0.06% | – |
| VTVT | Exit | VTV THERAPEUTICS INCcl a | $0 | – | -281,679 | -100.0% | -0.17% | – |
| PRGO | Exit | PERRIGO CO PLC | $0 | – | -19,221 | -100.0% | -0.24% | – |
| FGEN | Exit | FIBROGEN INC | $0 | – | -39,779 | -100.0% | -0.28% | – |
| EXPE | Exit | EXPEDIA GROUP INC | $0 | – | -18,900 | -100.0% | -0.32% | – |
| VBIV | Exit | VBI VACCINES INC | $0 | – | -666,284 | -100.0% | -0.35% | – |
| ERYP | Exit | ERYTECH PHARMAsponsored adr | $0 | – | -120,000 | -100.0% | -0.38% | – |
| ASNS | Exit | ARSANIS INC | $0 | – | -114,972 | -100.0% | -0.40% | – |
| BOLD | Exit | AUDENTES THERAPEUTICS INC | $0 | – | -95,000 | -100.0% | -0.43% | – |
| CHRS | Exit | COHERUS BIOSCIENCES INC | $0 | – | -270,000 | -100.0% | -0.45% | – |
| RGNX | Exit | REGENXBIO INC | $0 | – | -100,000 | -100.0% | -0.45% | – |
| CMTA | Exit | CLEMENTIA PHARMACEUTICALS IN | $0 | – | -200,000 | -100.0% | -0.46% | – |
| GEMP | Exit | GEMPHIRE THERAPEUTICS INC | $0 | – | -481,046 | -100.0% | -0.48% | – |
| ENDP | Exit | ENDO INTL PLC | $0 | – | -550,000 | -100.0% | -0.50% | – |
| NTLA | Exit | INTELLIA THERAPEUTICS INC | $0 | – | -160,000 | -100.0% | -0.51% | – |
| MGNX | Exit | MACROGENICS INC | $0 | – | -135,000 | -100.0% | -0.52% | – |
| REPH | Exit | RECRO PHARMA INC | $0 | – | -364,197 | -100.0% | -0.61% | – |
| PBYI | Exit | PUMA BIOTECHNOLOGY INC | $0 | – | -60,000 | -100.0% | -0.62% | – |
| SNDX | Exit | SYNDAX PHARMACEUTICALS INC | $0 | – | -298,472 | -100.0% | -0.64% | – |
| EIGR | Exit | EIGER BIOPHARMACEUTICALS INC | $0 | – | -475,000 | -100.0% | -0.71% | – |
| TSRO | Exit | TESARO INC | $0 | – | -106,175 | -100.0% | -0.92% | – |
| MNOV | Exit | MEDICINOVA INC | $0 | – | -630,838 | -100.0% | -0.98% | – |
| PTLA | Exit | PORTOLA PHARMACEUTICALS INCcall | $0 | – | -200,000 | -100.0% | -0.99% | – |
| LJPC | Exit | LA JOLLA PHARMACEUTICAL CO | $0 | – | -260,000 | -100.0% | -1.18% | – |
| CLVS | Exit | CLOVIS ONCOLOGY INC | $0 | – | -168,000 | -100.0% | -1.35% | – |
| QQQ | Exit | POWERSHARES QQQ TRUSTput | $0 | – | -80,000 | -100.0% | -1.94% | – |
| REGN | Exit | REGENERON PHARMACEUTICALS | $0 | – | -41,500 | -100.0% | -2.17% | – |
| CELG | Exit | CELGENE CORP | $0 | – | -319,000 | -100.0% | -4.32% | – |
| XBI | Exit | SPDR SERIES TRUSTput | $0 | – | -750,000 | -100.0% | -9.99% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-08-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICAL-SP ADR | 36 | Q3 2023 | 8.4% |
| MERCK & CO INC NEW | 35 | Q3 2023 | 8.4% |
| NICE Systems Ltd | 27 | Q3 2023 | 4.4% |
| BIOGEN INC | 26 | Q3 2023 | 6.7% |
| AMICUS THERAPEUTICS INC | 26 | Q2 2022 | 4.3% |
| PFIZER INC | 25 | Q3 2023 | 9.2% |
| SAREPTA THERAPEUTICS INC | 25 | Q3 2023 | 3.2% |
| JOHNSON & JOHNSON | 24 | Q3 2023 | 8.0% |
| UNIQURE NV | 23 | Q3 2023 | 1.2% |
| SYNDAX PHARMACEUTICALS INC | 22 | Q3 2023 | 3.9% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cyclacel Pharmaceuticals, Inc. | February 06, 2023 | 250,000 | 2.0% |
| Altimmune, Inc. | February 14, 2022 | 1,244,241 | 3.1% |
| Allot Ltd. | February 16, 2021 | 1,129,054 | 3.2% |
| Larimar Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Neos Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Orgenesis Inc. | February 16, 2021 | 525,216 | 0.0% |
| Sio Gene Therapies Inc. | February 16, 2021 | ? | ? |
| X4 Pharmaceuticals, Inc | February 16, 2021 | 250,000 | 0.0% |
| Axovant Gene Therapies Ltd. | February 25, 2020 | 2,931,017 | 8.0% |
| Axovant Gene Therapies Ltd. | February 11, 2020 | 398,540 | 1.8% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR/A | 2024-02-15 |
| 13F-HR | 2024-02-14 |
| SC 13G | 2024-02-08 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-10 |
| SC 13G | 2023-08-30 |
View SPHERA FUNDS MANAGEMENT LTD.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.